Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma
Open Access
- 19 March 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 39 (10), 605-611
- https://doi.org/10.1038/sj.bmt.1705627
Abstract
High-dose chemotherapy with stem cell transplantation (SCT) is feasible for elderly patients and patients with renal insufficiency. However, the impact of treatment on this patient population is unclear. We evaluated 678 consecutive patients with multiple myeloma who underwent SCT at Mayo Clinic. The complete response rate, time to progression and overall survival was recorded. Patients were stratified according to age (65 or >65 years) and serum creatinine value at the time of transplantation (2 or >2 mg/dl). Patient age did not have an effect on any outcome measure. Creatinine level did not affect complete response rate and time to progression, but patients with creatinine levels above 2 mg/ml had a higher day-100 mortality rate and a shorter overall survival rate. Platelet engraftment was also significantly delayed for patients with renal insufficiency. Selected patients over age 65 years may have outcomes identical to that of younger patients. When compared with patients with creatinine levels less than 2 mg/ml, patients with elevated creatinine levels had similar response rates and time to progression, but their overall survival was inferior. Transplantation should be offered to selected patients over age 65 years or selected patients with creatinine elevation.Keywords
This publication has 18 references indexed in Scilit:
- High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-AutogreffeJournal of Clinical Oncology, 2005
- Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failureEuropean Journal of Haematology, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialBlood, 2004
- Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplantBone Marrow Transplantation, 2004
- Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of ageBone Marrow Transplantation, 2003
- Are myeloma patients with renal failure candidates for autologous stem cell transplantation?The Hematology Journal, 2000
- The role of autologous transplantation in patients with multiple myeloma aged 65 years and overBone Marrow Transplantation, 2000
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996